| Expression pattern: |
UP |
| Associated gene: |
CMTM4, CMTM6, PD-L1 |
| Associated microRNA: |
microRNA-7, miR7, miR-7 |
| Biological function: |
CDR1-AS expression increases CMTM4 and CMTM6 transcript levels and cell surface PD-L1 protein levels in colon cancer cells, while cell growth, invasion ability, and angiogenesis were not altered. |
| Molecular mechanism: |
CDR1-AS increases CMTM4 and CMTM6 expression and cell surface PD-L1 protein levels through microRNA-7-independent mechanisms; the authors suggest undefined factors, possibly transcription factors, may mediate CMTM4/CMTM6 upregulation. |
| Biological pathway or process: |
immune regulation (promotes); ceRNA regulation (other); other pathway/process (promotes) |
| Detected method: |
Q
B
|
| Validation methods: |
RNase R Treatment; Northern Blot; RT-qPCR; Microarray; Transfection; Luciferase Reporter Assay; CCK8; Transwell Assay; Tube Formation Assay; Flow Cytometry（Non-apoptosis/cycle）; IHC (Immunohistochemistry); In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
CDR1-AS expression is linked with poor prognosis, and high CDR1-AS expression levels have been correlated with poor survival in colon cancer patients; the study suggests this may be explained by increased cell surface PD-L1. |
| Description: |
This study shows that CDR1-AS expression in colon cancer cells increases CMTM4 and CMTM6 transcript levels and elevates cell surface PD-L1 protein levels. The PD-L1 increase is not reversed by miR7 mimic overexpression, indicating a microRNA-7-independent mechanism. The authors propose that this onco-immunological effect may help explain the poor prognosis associated with high CDR1-AS expression in colon cancer. |
| Confidence score: |
0.753 |